pirfenidone

01/01/2016 - "Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis."
01/01/2014 - "Pirfenidone is a new antifibrotic drug, which has been proven beneficial in idiopathic pulmonary fibrosis and is able to inhibit or reverse BIP in animal models. "
11/01/2022 - "Overall, Pirfenidone may be an effective and well-tolerated treatment option for idiopathic pulmonary fibrosis."
01/01/2016 - "Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function."
10/28/2011 - "A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). "

01/01/2019 - "PIROUETTE will determine whether pirfenidone is superior to placebo in relation to regression of myocardial fibrosis and improvement in myocardial energetics in patients with HFpEF and myocardial fibrosis (NCT02932566). "
01/01/2020 - "Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?"
10/01/2018 - "Of note, pirfenidone has been tested in animal models of cardiac fibrosis and was found to be effective in reducing ventricular remodelling. "
09/01/2010 - "Although the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease."
01/01/2021 - "Pirfenidone has been recently tested in animal models of myocardial fibrosis with promising results. "

01/01/2020 - "To demonstrate our hypothesis, we compared the therapeutic efficacy of varying doses of pirfenidone administered by oral and intranasal routes in a human transforming growth factor-β1 transgenic mouse with established pulmonary fibrosis. "
01/01/2020 - "We hypothesized that low-dose intrapulmonary delivery of pirfenidone is effective in human transforming growth factorβ1-driven pulmonary fibrosis. "
01/01/2020 - "Pirfenidone (PFD) is effective for pulmonary fibrosis (PF), but its action mechanism has not been fully explained. "
06/01/2005 - "Pirfenidone is an investigational anti-fibrotic agent shown to be effective in blocking pulmonary fibrosis. "
06/01/2011 - "The current, randomized, placebo-controlled, prospective, double-blind trial investigated the safety and efficacy of pirfenidone for mild to moderate HPS-1 and 4 pulmonary fibrosis. "

12/01/2020 - "Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't."
01/01/2020 - "This study examined the efficacy of pirfenidone in patients with IPF and fibrotic idiopathic non-specific interstitial pneumonia (f-iNSIP). "
01/01/2022 - "Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis."
10/13/2023 - "The aim of the study was to examine the best-tolerated dose of pirfenidone, the adverse effects profile, and potential factors other than drug dose influencing the tolerability of pirfenidone in patients with fibrosing interstitial lung diseases (ILDs). "
01/01/2022 - "There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this population can benefit from pirfenidone. "

10/26/2023 - "In our study, regardless of dose, consistent pirfenidone use for 12 months resulted in similar efficacy for the prevention of disease progression in patients with IPF. "
10/26/2023 - "The aim of this study was to evaluate the efficacy of different doses of pirfenidone for the prevention of disease progression in patients with IPF. "
06/03/2022 - "Clinical trials verifying the use of pirfenidone after disease progression in IPF may be difficult to enroll patients. "
06/03/2022 - "A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. "
01/01/2021 - "This study evaluated the effects of low-dose pirfenidone on IPF disease progression and patient survival in the real-world. "